US FDA cites misleading ad for periodontal treatment
This article was originally published in Scrip
Executive Summary
A journal ad for Dexcel Pharma Technologies' periodontal treatment PerioChip (chlorhexidine gluconate) fails to communicate any risk information, the US FDA's division of drug marketing, advertising and communications (DDMAC) said in a recent warning letter.